Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The immunoregulatory molecules programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) are associated with the dysfunction of antiviral effector T-cells, which leads to T-cell exhaustion and persistent viral infection in patients with chronic hepatitis C and chronic hepatitis B. Little is known about the role of PD-1 and CTLA-4 in patients with symptomatic acute hepatitis A (AHA). Methods: Peripheral blood mononuclear cells were isolated from seven patients with AHA and from six patients with nonviral acute toxic hepatitis (ATH) during the symptomatic and convalescent phases of the respective diseases; five healthy subjects acted as controls. The expression of PD-1 and CTLA-4 on T-cells was measured by flow cytometry. Results: PD-1 and CTLA-4 expression during the symptomatic phase was significantly higher in the Tcells of AHA patients than in those of ATH patients or healthy controls (PD-1: 18.3% vs 3.7% vs 1.6%, respectively, p<0.05; CTLA-4: 23.5% vs 6.1% vs 5.9%, respectively, p<0.05). The levels of both molecules decreased dramatically during the convalescent phase of AHA, whereas a similar pattern was not seen in ATH. Conclusions: Our findings are consistent with a viral-protective effect of PD-1 and CTLA-4 as inhibitory molecules that suppress cytotoxic T-cells and thereby prevent the destruction of virus-infected hepatocytes in AHA.
Abstract
Background/Aims: The immunoregulatory molecules programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) are associated with the dysfunction of antiviral effector T-cells, which leads to T-cell exhaustion and persistent viral infection in patients with chronic hepatitis C and chronic hepatitis B. Little is known about the role of PD-1 and CTLA-4 in patients with symptomatic acute hepatitis A (AHA). Methods: Peripheral blood mononuclear cells were isolated from seven patients with AHA and from six patients with nonviral acute toxic hepatitis (ATH) during the symptomatic and convalescent phases of the respective diseases; five healthy subjects acted as controls. The expression of PD-1 and CTLA-4 on T-cells was measured by flow cytometry. Results: PD-1 and CTLA-4 expression during the symptomatic phase was significantly higher in the Tcells of AHA patients than in those of ATH patients or healthy controls (PD-1: 18.3% vs 3.7% vs 1.6%, respectively, p<0.05; CTLA-4: 23.5% vs 6.1% vs 5.9%, respectively, p<0.05). The levels of both molecules decreased dramatically during the convalescent phase of AHA, whereas a similar pattern was not seen in ATH. Conclusions: Our findings are consistent with a viral-protective effect of PD-1 and CTLA-4 as inhibitory molecules that suppress cytotoxic T-cells and thereby prevent the destruction of virus-infected hepatocytes in AHA.
참고문헌 (15)
- De Filippis P, "Detection of hepatitis A virus in the stools of healthy people from endemic areas", Eur J Epidemiol, 3, pp.172~175 (1987)
- Kwon SY, "Current status of liver diseases in Korea: hepatitis A", Korean J Hepatol, 15(6), pp.S7~S12 (2009)
- Fife BT, "Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways", Immunol Rev, 224, pp.166~182 (2008)
- Nakamoto N, "Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1", CTLA-4 blockade, 2009, pp.5, e1000313~
- Evans A, "Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion", Hepatology, 48, pp.759~769 (2008)
- Day CL, "PD-1 expression on HIVspecific T cells is associated with T-cell exhaustion and disease progression", Nature, 443, pp.350~354 (2006)
- Kaufmann DE, "PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention", J Immunol, 182, pp.5891~5897 (2009)
- Elrefaei M, "Presence of suppressor HIV-specific CD8+ T cells is associated with increased PD-1 expression on effector CD8+ T cells", J Immunol, 180, pp.7757~7763 (2008)
- Sugimoto K, "Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection", Hepatology, 38, pp.1437~1448 (2003)
- Ebinuma H, "Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection", J Virol, 82, pp.5043~5053 (2008)
- Nakamoto N, "Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization", Gastroenterology, 134(e2), pp.1927~1937 (2008)
- Freeman GJ, "Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade", J Exp Med, 203, pp.2223~2227 (2006)
- Golden-Mason L, "Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction", J Virol, 81, pp.9249~9258 (2007)
- Wenjin Z, "Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B", BMC Gastroenterol, 12, pp.109~ (2012)
- Wang L, "Expression levels of CD28, CTLA-4, PD-1 and Tim-3 as novel indicators of T-cell immune function in patients with chronic hepatitis B virus infection", Biomed Rep, 2, pp.270~274 (2014)